Taltz
E133652
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Taltz canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T1168576 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Taltz Context triple: [Eli Lilly and Company, notableProduct, Taltz]
-
A.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
B.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
C.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Taltz Target entity description: Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
A.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
B.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
C.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
D.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
interleukin-17 inhibitor ⓘ monoclonal antibody ⓘ prescription drug ⓘ |
| belongsToPharmacologicClass |
immunosuppressant
ⓘ
selective immunomodulator ⓘ |
| hasActiveIngredient | ixekizumab ⓘ |
| hasATCCode | L04AC13 ⓘ |
| hasBrandOwner | Eli Lilly and Company ⓘ |
| hasCommonAdverseEffect |
injection site reactions
ⓘ
nausea ⓘ oral candidiasis ⓘ tinea infections ⓘ upper respiratory tract infection ⓘ |
| hasDosageForm |
solution for injection in prefilled autoinjector
ⓘ
solution for injection in prefilled syringe ⓘ |
| hasFirstFDAApprovalYear | 2016 ⓘ |
| hasGenericName | ixekizumab ⓘ |
| hasIndication |
treatment of active ankylosing spondylitis
ⓘ
treatment of active psoriatic arthritis ⓘ treatment of adults with moderate to severe plaque psoriasis ⓘ treatment of non-radiographic axial spondyloarthritis with objective signs of inflammation ⓘ |
| hasLoadingDose | yes ⓘ |
| hasMaintenanceDoseInterval | every 4 weeks ⓘ |
| hasPregnancyCategory | insufficient human data ⓘ |
| hasRouteOfAdministration | subcutaneous injection ⓘ |
| hasSeriousAdverseEffect |
hypersensitivity reactions
ⓘ
serious infections ⓘ |
| hasWarning |
may increase risk of infections
ⓘ
use with caution in patients with inflammatory bowel disease ⓘ |
| isAdministeredBy | healthcare professional or patient self-injection ⓘ |
| isAdministeredTo |
adults
ⓘ
children 6 years and older for plaque psoriasis ⓘ |
| isApprovedBy |
European Medicines Agency
ⓘ
Food and Drug Administration ⓘ
surface form:
U.S. Food and Drug Administration
|
| isContraindicatedIn | patients with serious hypersensitivity to ixekizumab ⓘ |
| isManufacturedBy | Eli Lilly and Company ⓘ |
| isUsedFor |
ankylosing spondylitis
ⓘ
moderate to severe plaque psoriasis ⓘ non-radiographic axial spondyloarthritis ⓘ pediatric plaque psoriasis ⓘ psoriatic arthritis ⓘ |
| mechanismOfAction | selective inhibition of interleukin-17A ⓘ |
| modulates | immune system ⓘ |
| requiresMonitoring |
signs and symptoms of infection
ⓘ
tuberculosis status before initiation ⓘ |
| targets |
IL-17A
ⓘ
interleukin-17A ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Taltz Description of subject: Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.